First Trust Advisors LP Has $44.21 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

First Trust Advisors LP decreased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 50.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 330,860 shares of the life sciences company's stock after selling 335,250 shares during the quarter. First Trust Advisors LP owned about 0.21% of Illumina worth $44,213,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina in the 4th quarter worth $32,000. Assetmark Inc. boosted its holdings in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after acquiring an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Illumina during the fourth quarter worth about $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in shares of Illumina in the 4th quarter valued at about $48,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Down 1.0 %

Shares of ILMN traded down $0.79 during mid-day trading on Tuesday, reaching $76.43. The company's stock had a trading volume of 274,257 shares, compared to its average volume of 2,274,181. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a market cap of $12.10 billion, a price-to-earnings ratio of -9.97, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The business has a fifty day moving average of $81.51 and a 200 day moving average of $117.39.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several recent research reports. Piper Sandler lifted their target price on shares of Illumina from $185.00 to $190.00 and gave the company an "overweight" rating in a report on Monday, February 10th. TD Cowen downgraded Illumina from a "buy" rating to a "hold" rating and decreased their target price for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. Citigroup reduced their price target on Illumina from $90.00 to $85.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. Finally, Canaccord Genuity Group dropped their target price on shares of Illumina from $115.00 to $92.00 and set a "hold" rating on the stock in a report on Tuesday. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $137.55.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.